Thursday, March 20, 2025 9:57:09 AM
Ansys plays a significant role in the development and optimization of electroporation devices through its simulation software. Here's how:
Ansys and Electroporation Device Design:
Electromagnetic Field Simulation:
Ansys software, particularly Ansys HFSS and Ansys Maxwell, allows engineers to simulate the electromagnetic fields generated by electroporation devices.
This is crucial for optimizing electrode design, pulse parameters, and overall device performance.
These simulations help to understand the distribution of electric fields within the targeted tissue, ensuring effective electroporation.
Multiphysics Analysis:
Electroporation involves complex interactions between electrical fields, biological tissues, and sometimes heat transfer.
Ansys provides multiphysics capabilities, enabling engineers to simulate these coupled phenomena.
This allows for the analysis of thermal effects, mechanical stresses, and other factors that can influence electroporation outcomes.
Device Optimization:
By using Ansys simulations, engineers can:
Optimize electrode geometry to achieve desired electric field distributions.
Determine optimal pulse parameters (voltage, duration, frequency).
Evaluate the impact of tissue properties on electroporation efficiency.
Improve device safety and reliability.
Applications:
These simulations are valuable for a wide range of electroporation applications, including:
Gene therapy.
Drug delivery.
Cancer treatment.
Food processing.
In essence:
Ansys simulation software provides a powerful toolset for designing and optimizing electroporation devices, enabling engineers to create more effective and safer technologies. This is done by simulating the electrical fields, and the effect those fields have on the materials that the device is being used on.
Ansys and Electroporation Device Design:
Electromagnetic Field Simulation:
Ansys software, particularly Ansys HFSS and Ansys Maxwell, allows engineers to simulate the electromagnetic fields generated by electroporation devices.
This is crucial for optimizing electrode design, pulse parameters, and overall device performance.
These simulations help to understand the distribution of electric fields within the targeted tissue, ensuring effective electroporation.
Multiphysics Analysis:
Electroporation involves complex interactions between electrical fields, biological tissues, and sometimes heat transfer.
Ansys provides multiphysics capabilities, enabling engineers to simulate these coupled phenomena.
This allows for the analysis of thermal effects, mechanical stresses, and other factors that can influence electroporation outcomes.
Device Optimization:
By using Ansys simulations, engineers can:
Optimize electrode geometry to achieve desired electric field distributions.
Determine optimal pulse parameters (voltage, duration, frequency).
Evaluate the impact of tissue properties on electroporation efficiency.
Improve device safety and reliability.
Applications:
These simulations are valuable for a wide range of electroporation applications, including:
Gene therapy.
Drug delivery.
Cancer treatment.
Food processing.
In essence:
Ansys simulation software provides a powerful toolset for designing and optimizing electroporation devices, enabling engineers to create more effective and safer technologies. This is done by simulating the electrical fields, and the effect those fields have on the materials that the device is being used on.
Recent INO News
- Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China • PR Newswire (US) • 05/21/2026 08:05:00 PM
- INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights • PR Newswire (US) • 05/13/2026 08:05:00 PM
- INOVIO to Participate in Upcoming Scientific Conferences • PR Newswire (US) • 05/08/2026 12:05:00 PM
- INOVIO to Report First Quarter Financial Results on May 13, 2026 • PR Newswire (US) • 05/01/2026 08:05:00 PM
- INO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Inovio Pharmaceuticals, Inc. Securities Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/07/2026 01:00:00 PM
- Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO • PR Newswire (US) • 04/06/2026 07:46:00 AM
- INOVIO Announces Pricing of $17.5 Million Public Offering • PR Newswire (US) • 04/02/2026 12:55:00 PM
- INOVIO Announces Proposed Public Offering • PR Newswire (US) • 04/02/2026 12:05:00 AM
- INOVIO to Participate in Upcoming Scientific Conference • PR Newswire (US) • 04/01/2026 02:29:00 PM
- INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 03/31/2026 01:00:00 PM
- Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO • PR Newswire (US) • 03/30/2026 07:47:00 AM
- INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 03/24/2026 01:00:00 PM
- INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 03/17/2026 01:00:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/12/2026 08:05:00 PM
- Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO • PR Newswire (US) • 03/10/2026 01:00:00 PM
- INOVIO to Participate in Upcoming Scientific Conferences • PR Newswire (US) • 03/09/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:55:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:54:42 PM
- INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 • PR Newswire (US) • 03/05/2026 09:05:00 PM
- INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) • PR Newswire (US) • 03/04/2026 01:05:00 PM
- Inovio Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO • PR Newswire (US) • 03/03/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:49:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:48:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:47:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:47:13 PM
